Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe

Pharmacotherapy

Volumn 29, Issue 10, 2009, Pages 1175-1181

  Schmitt, Christophe ^a   Hofmann, Carsten ^a   Riek, Myriam ^a   Patel, Arpna ^b   Zwanziger, Elke ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cytochrome P450; Drug interaction; Midazolam; Ritonavir; Saquinavir

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM; RITONAVIR PLUS SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CONTUSION; CROSSOVER PROCEDURE; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; INFECTION; INNER EAR DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NORMAL HUMAN; ORAL HYPOESTHESIA; OTOTOXICITY; RESPIRATORY TRACT DISEASE; SEDATION; SIDE EFFECT; THORAX DISEASE; UNSPECIFIED SIDE EFFECT;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; PROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR;

EID: 70349670588     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1175     Document Type: Article

References (21)

1. ▶1. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
2. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-266
3. ▶3. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194
4. Roche Laboratories Inc. Invirase (saquinavir mesylate) product information. Nutley, NJ; 2007.
5. ▶5. Hsu A, Granneman GR, Bertz RJ. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291
6. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-136
7. Frye R, Bertz RJ, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Presented at the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
8. Kanto JH. Midazolam, the first water-soluble benzodiazepine: pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia. Pharmacotherapy 1985;5:138-155
9. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556
10. Crevoisier C, Ziegler WH, Eckert M, Heizmann P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983;16(suppl 1):S51-61.
11. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-728
12. ▶12. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-1653
13. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed., New York, NY: Marcel Dekker, Inc., 1982.
14. ▶14. Kaeser B, Zhang X, Zandt H, et al. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53:609-614
15. ▶15. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-39
16. ▶16. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
17. ▶17. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
18. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
19. Ernest CS II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312:583-591 (Pubitemid 40189555)
20. ▶20. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008;49:358-368
21. ▶21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471